These data confirm that in Polish clinical practice, GLP-1 RAs are increasingly used in the pharmacotherapy of obesity, which is consistent with current international guidelines recommending the use of liraglutide, semaglutide, and tirzepatide in the treatment of obesity [13]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.